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Abstract
Background: Cancer screening guidelines reflect the costs and benefits of population-based screening based on 
evidence from clinical trials. While most of the existing literature on compliance with cancer screening guidelines only 
measures raw screening rates in the target age groups, we used a novel approach to estimate degree of guideline 
compliance across Canadian provinces for breast, colorectal and prostate cancer screening. Measuring compliance as 
the change in age-specific screening rates at the guideline-recommended initiation age (50), we generally found 
screening patterns across Canadian provinces that were not consistent with guideline compliance.
Methods: We calculated age-cancer-specific screening rates for ages 40-60 using the Canadian Community Health 
Survey (2003 and 2005), a cross-sectional, nationally representative survey of health status, health care utilization and 
health determinants in the Canadian population. We estimated the degree of compliance using logistic regression to 
measure the change in adjusted screening rates at the guideline-recommended initiation age for each province in the 
sample.
Results: For breast cancer, after adjusting for age trends and other covariates, being above age 50 in Quebec increased 
the probability of being screened by 19 percentage points, from an average screening rate of 24% among 40-49 year 
olds. None of the other regions exhibited a statistically significant change in screening rates at age 50. Additional 
analyses indicated that these patterns reflect asymptomatic screening and that Quebec's breast cancer screening 
program enhanced the degree of guideline compliance in that province. Colorectal cancer screening practice was 
consistent with guidelines only in Saskatchewan, as screening rates increased at age 50 by 12 percentage points, from 
an average rate of 6% among 40-49 year olds. For prostate cancer, the regions examined here are not compliant with 
Canadian guidelines since screening rates were quite high, and there was not a discrete increase at any particular age.
Conclusions: Screening practice for breast, colorectal and prostate cancer was generally not consistent with Canadian 
clinical guidelines. Quebec (breast) and Saskatchewan (colorectal) were exceptions to this, and the impact of Quebec's 
breast cancer screening program suggests a role for policy in improving screening guideline compliance.
Background
Clinical guidelines codify and transmit existing knowl-
edge regarding best practice and aid physicians and
patients in choosing optimal treatment. The extent to
which Canadian patients and physicians follow, or com-
ply with, such guidelines for cancer screening remains
largely unknown. Studies that examine Canadian cancer
screening practice generally conclude that breast and col-
orectal cancer screening rates are low, relative to the
guideline recommendation that everyone in a given age
group be screened, while prostate cancer screening rates
are high. In 2003, 26% of women had not had a mammo-
gram within the last two years [1] and 58% of Canadians
ages 50 and over had never had a fecal occult blood test
(FOBT) or endoscopy [2]. Meanwhile, approximately half
of men over age 50 have received a prostate-specific anti-
gen (PSA) test in their lifetime [3] and men between the
ages of 50 to 69 are two- to three-times more likely to be
screened for prostate cancer than colorectal cancer, even
though PSA testing is not generally recommended in
Canada [4]. These and other existing studies generally
focus on screening rates in the age group recommended
for screening [5-7].
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By specifying the age at which screening should begin,
the guidelines implicitly recommend that screening not
occur for asymptomatic individuals below that age, often
due to low specificity of the test and the health conse-
quences of unnecessary intervention and treatment. A
high screening rate among the target age group does not
necessarily reflect compliance if, for example, screening
rates are also high among age groups not recommended
for screening. We therefore expect that in regions where
guidelines are being followed, a sharp change in popula-
tion screening rates will be evident at the guideline-rec-
ommended initiation age. We measured guideline
compliance using a novel measure: the change in screen-
ing rates among age groups below the recommended ini-
tiation age and those above the threshold. Only two other
studies conceive of compliance in this way [8,9], but nei-
ther examined population screening rates. We believe
this is an important complimentary definition of screen-
ing compliance that more accurately reflects the guide-
lines themselves and has implications for both clinical
practice and health care policy.
This study examined the degree of compliance with
national screening guidelines for breast, colorectal, and
prostate cancer, defined as the change in screening rates
at the guideline-recommended initiation age. Specifically,
we used logistic regression to test for a statistically signif-
icant change in adjusted screening rates at the guideline-
r ec ommended initia tion age. W e also in vestiga t ed how
t h i s  d e f i n i t i o n  o f  c o m p l i a n c e  v a r i e s  a c r o s s  C a n a d i a n
provinces and addressed the role of provincial screening
programs for breast cancer.
Cancer screening guidelines and provincial cancer 
screening programs
Table 1 presents cancer screening guidelines from the
Canadian Task Force on Preventive Health Care and the
Canadian Cancer Society that were in place during the
study period (2003-2005). These guidelines were based
on results from clinical trials and specified which screen-
ing tests should be used, the periodicity of screening, and
the target population [10]. These evidence-based recom-
mendations were relevant across Canada for asymptom-
atic individuals without a family history of cancer.
Provincial screening programs also have the potential
to influence screening rates and compliance with guide-
lines. All ten provinces had breast cancer screening pro-
grams in place during the study period, with British
Columbia starting in 1988 and Prince Edward Island
being the last to introduce a program in 1999. All pro-
grams focused on mammography as the preferred screen-
ing method and targeted asymptomatic women ages 50-
69, except BC which screened women ages 40-79 [11-20].
These programs aimed to increase screening rates via
awareness (advertising and individual reminder letters)
and improved access (mobile screening units), but their
impact on compliance with guidelines is unknown. Orga-
nized screening programs for colorectal and prostate
cancer are not relevant given the time frame of this study,
since Alberta, Manitoba and Ontario began colorectal
cancer screening programs in 2007 and BC only recently
initiated a program for prostate cancer screening [21-24].
Methods
Study population and data
We estimated age-specific screening rates using the 2003
and 2005 Canadian Community Health Survey (CCHS)
microdata files accessed through a Statistics Canada
Research Data Center. The CCHS is a cross-sectional,
nationally representative survey of health status, health
care utilization and health determinants in the Canadian
population with an overall response rate of 81% in 2003
and 79% in 2005 [25,26]. The analyzed regions varied
across cancer type due to differences in the administra-
tion of survey questions across provinces and minimum
sample size requirements from Statistics Canada. For
breast cancer, we examined screening rates in the Atlan-
tic region (Newfoundland and Labrador, Prince Edward
Island, Nova Scotia and New Brunswick combined), Que-
bec, Ontario, the Prairies (Manitoba, Saskatchewan and
Alberta combined), and British Columbia. All health
regions administered the breast cancer screening mod-
ule. For colorectal cancer, we analyzed the Atlantic
region, Ontario, Saskatchewan and British Columbia and
for prostate cancer, the Atlantic region (not including
Nova Scotia), Ontario and British Columbia. We used
two years of the CCHS because the colorectal and pros-
tate cancer screening questions were asked in different
provinces in different years (colorectal cancer screening:
Saskatchewan (7 of 11 health regions) and British Colum-
bia in 2003, Atlantic provinces and Ontario in 2005; pros-
tate cancer screening: Ontario (24 of 37 health regions)
and British Columbia in 2003, Atlantic provinces in 2005.
All health regions unless otherwise noted.).
We collected screening and expenditure data from
provinces' breast cancer screening programs, as well as
the date the program began and their target population
[27-37]. Most provincial programs were already in exis-
tence over the time period for which CCHS screening
data exist, and only limited expenditure data was avail-
able. We combined this information with data from the
National Population Health Survey (1994/95-1998/99)
and the CCHS from 2001-2005 to evaluate the impact of
screening programs on guideline compliance.
Statistical analysis
To estimate guideline compliance, separate cross-sec-
tional logistic regressions were estimated for each type of
cancer, by region, on a gender-appropriate sample ofStrumpf et al. BMC Cancer 2010, 10:304
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adults ages 40-60. Dependent variables indicated receipt
of screening in the past two years for breast (mammogra-
phy), colorectal (sigmoidoscopy, colonoscopy or FOBT),
and prostate cancer (PSA test). This measure captured a
"point-in-time" estimate of the percent of individuals
screened at different ages and did not focus on individu-
als' screening histories over time. An indicator variable
for being above the guideline-recommended initiation
age (age 50+) was the key independent variable. Covari-
ates included age trends (age, age2, age3), sex (for colorec-
tal screening), race (white and non-white), education (less
than secondary, secondary graduate, some post-second-
ary, and post-secondary graduate), household income
quartile, and marital status (married, divorced or sepa-
rated, widowed, never married, and unmarried couple).
W e  c o n v e r t e d  a d j u s t e d  o d d s - r a t i o s  t o  r e l a t i v e  r i s k s  b y
calculating the ratio of predicted probabilities of being
above versus below the age threshold, with confounders
at their mean (i.e., marginal effects) [38]. All analyses
accounted for the survey's complex sampling frames and
data were weighted to be nationally representative.
To allay concerns that our results were driven by a
sharp increase in symptomatic screening at age 50, and
therefore should not be interpreted in the context of
guideline compliance, we ran a parallel analysis to that
described above. Here the dependent variable equaled
one if the respondent's reason for receiving the test in the
past two years was "age" or "regular check-up" and equal
to zero if they received the test for another reason (family
history, previously detected lump, breast problem, hor-
mone replacement therapy, or follow-up treatment) or
have not received the test in the past two years.
Organized provincial breast cancer screening programs
are likely to increase screening rates, but whether they
improve adherence to clinical guidelines is an open ques-
tion. Because screening programs may affect screening
rates and guideline compliance through several different
avenues ranging from increased publicity and awareness
to increased access to screening outside physicians'
offices, we continued to use the self-reported measure of
screening from any source from the CCHS. Data limita-
tions allowed us to examine only the impact of the intro-
duction of Quebec's program (Programme québécois de
dépistage du cancer du sein) in 1998, by comparing the
change in screening rates at age 50 before the program
was in place to the change at age 50 after implementation.
In a logistic regression similar to that outlined above, an
indicator variable equal to zero in years before the pro-
gram's start and one after was interacted with the variable
indicating age 50 or above.
Results
Breast cancer
Figure 1 shows the percent of Canadian women who had
a mammogram in 2005 by region and by year of age. In
Canada overall, screening rates increased significantly
Table 1: Canadian cancer screening guidelines from the Canadian Task Force on Preventive Health Care (CTFPHC) and the 
Canadian Cancer Society (CCS)
Breast Cancer Colorectal Cancer Prostate Cancer
CTFPHC (2001) [44] CTFPHC (2001) [45] CTFPHC (2000) [46]
Test Mammography FOBT (good evidence); 
sigmoidoscopy (fair evidence); 
insufficient evidence to include or 
exclude colonoscopy
PSA
Periodicity Every 1-2 years Every 1 to 2 years; periodicity 
unspecified
Not be used due to low positive 
predictive value and risk of adverse 
affects associated with treatment
Population Asymptomatic women ages 50-69 Asymptomatic individuals age 50+ NA
CCS (2005) [47] CCS(2005) [48] CCS (2005) [49]
Test Mammography FOBT PSA
Periodicity Every 2 years At least every 2 years Discuss with physician the benefits 
and risks
Population Asymptomatic women ages 50-69 Asymptomatic individuals age 50+ Men age 50+
*No changes have occurred with the recommendations set forth by the Canadian Cancer Society since 1997.Strumpf et al. BMC Cancer 2010, 10:304
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from 47% at age 49, to 57% and 66% at ages 50 and 51,
respectively. When broken down by province, Quebec
demonstrated the clearest adherence to the guidelines,
with screening rates increasing from 48% at age 49 to 67%
at 51. Ontario displayed a similar but less substantial
jump at age 50, while the other three regions showed no
apparent change. The graphs suggest that physicians and
women followed the national guidelines in at least some
regions. However, they also show a general upward trend
in mammography rates as women age and possible dis-
crete shifts at ages other than 50. For example, the screen-
ing rate in British Columbia almost doubled from 13% at
age 39, to 25% at age 41, potentially indicating a trend
break at age 40 that did not adhere to national guidelines
but was consistent with BC's provincial screening pro-
gram. Trend breaks at age 40 for breast cancer screening
would also be consistent with compliance U.S. breast can-
cer screening guidelines. We used regression analysis to
test whether these apparent trend breaks at different ages
persisted after controlling for age trends and other con-
founders.
Across provinces, logistic regression analysis showed
that being over age 50 increased breast cancer screening
rates by 9.9 percentage points [OR = 1.49; p = .002] (Kadi-
yala S and Strumpf EC: Are U.S. and Canadian cancer
screening rates consistent with guideline information
regarding the age of screening initiation?, submitted).
Table 2 presents the logistic regression results and shows
that, after adjusting for age trends and other covariates,
being above age 50 in Quebec increased the probability of
being screened by 19.3 percentage points [OR = 2.19; p =
0.004] (Additional file 1, available in an attachment, pro-
vides the full set of regression coefficients). None of the
other regions studied exhibited significant changes in
screening rates at age 50. A separate regression analysis
(not shown) examined the impact of being over age 40 on
screening rates among women ages 35-55. Mammogra-
phy rates did not change significantly at age 40 after con-
trolling for covariates in British Columbia, but in Quebec
[OR = 2.014; p = 0.049] and the Prairie provinces [OR =
2.261; p = 0.026] instead. It is worth noting that, although
women in higher income quartiles were more likely to be
screened in all provinces except Quebec, income was not
generally a significant predictor of guideline compliance.
Colorectal cancer
Despite clear clinical guidelines and the inclusion of sev-
eral different screening methods in this analysis, colorec-
tal cancer screening rates were quite low. Figure 2 plots
colorectal screening by age for men and women com-
bined. Screening rates rose from 15% at age 49 to 17% at
age 50 and 21% at age 51 in Canada. These rates showed a
more visible change collectively at the age 50 threshold
than each region separately, with the exception of Sas-
katchewan.
Across provinces, regression results showed a 1.3 per-
centage point increase in colorectal cancer screening
rates at age 50 [OR = 1.11; p = .53] (Kadiyala S and
Strumpf EC: Are U.S. and Canadian cancer screening
rates consistent with guideline information regarding the
age of screening initiation?, submitted). Table 2 presents
the regression results for colorectal screening by region,
controlling for age trends and other covariates, including
gender. Being above the age threshold in Saskatchewan
increased the probability of being screened by 12.5 per-
centage points [OR = 3.62; p = 0.036]. In contrast, we did
not observe significant changes in screening rates at age
50 in the Atlantic provinces, Ontario, or British Colum-
bia.
Prostate cancer
While national guidelines do not recommend the use of
PSA tests, Figure 3 shows that age-specific rates were rel-
atively high in Canada. About 35 percent of 50 year old
men reported having received a PSA test in the past two
years. However, beyond the trend of screening rates
increasing with age, there did not appear to be a discrete
increase at any particular age in Canada overall or in any
of the regions we examined.
Across provinces, there was no significant change in
prostate cancer screening rates at age 50 [OR = 1.043, p =
.843] (Kadiyala S and Strumpf EC: Are U.S. and Canadian
cancer screening rates consistent with guideline informa-
tion regarding the age of screening initiation?, submit-
ted). Table 2 presents the regression results by region
controlling for age trends and demographics. Consistent
with Figure 3, it shows no statistically significant change
in adjusted screening rates at age 50.
Figure 1 Percent of Women Who Report Mammography Screen-
ing in the Previous Two Years, by Year-of-Age, 2005.
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Preventive vs. symptomatic screening
The national cancer screening guidelines only applied to
asymptomatic individuals without a family history of the
disease. The results using asymptomatic screening as the
dependent variable matched those presented above very
closely. For breast cancer, there was a sharp increase in
asymptomatic screening rates of 17 percentage points at
age 50 in Quebec [OR 2.42, p = 0.002, CI 1.39-4.22], but
not in any other region. For colorectal cancer, there was a
very small increase in asymptomatic screening at age 50
only in Saskatchewan [OR .002, CI 0.00-0.84], suggesting
that the increase shown in Table 2 is due to "symptom-
atic" reasons. None of the regions exhibited a statistically
significant change in asymptomatic prostate cancer
screening rates at age 50.
The role of provincial screening programs
After controlling for the same set of demographic vari-
ables and adding year indicators to control for changes in
screening rates over time, breast cancer screening rates
for women age 50 and above were 25 percentage points
higher after the initiation of the Quebec program than for
the same age group before the program was in place [OR
2.81, CI 1.71, 4.61]. This result indicates that our measure
of guideline compliance increased significantly after pro-
gram implementation. Notably, because no organized
screening programs for prostate or colorectal cancer were
in place at the time of this study, the rates presented here
for those screening types can be interpreted as baseline,
pre-program rates.
Table 2: Impact of guideline initiation age on cancer screening - adjusted odds ratio of being at or above the guideline 
recommended initiation age
Dependent variable breast: Received mammogram in the past 2 years
Dependent variable colorectal: Received FOBT test, sigmoidoscopy or colonoscopy in the past 2 years
Dependent variable prostate: Received PSA test in the past 2 years
Adjusted Odds Ratio (95% Confidence Interval)
Breast Colorectal Prostate
Atlantic 1.70 0.92 1.22
(0.86, 3.35) (0.45, 1.89) (0.50, 2.96)
Quebec 2.19**
(1.29, 3.72)
Ontario 1.32 1.12 1.16
(0.85, 2.05) (0.74, 1.69) (0.63, 2.12)
Saskatchewan 3.62*
(1.09, 12.05)
Prairies 1.31
(0.71, 2.42)
British Columbia 1.21 0.99 1.01
(0.60, 2.43) (0.52, 1.89) (0.48, 2.12)
*** p <= .001, **p <= .01, * p <= .05. Notes: Each coefficient comes from a separate logistic regression which includes controls for age, age2 
and age3; race (white/non-white), marital status (5 categories), education (4 categories), household income quartiles, and sex (for colorectal).
Marginal effects for the age cutoff variable (breast): Atlantic 12.95, Quebec 19.34, Ontario 6.87, Prairies 6.76, British Columbia 4.69
Marginal effects for the age cutoff variable (colorectal): Atlantic -0.82, Ontario 1.48, Saskatchewan 12.51, BC -0.11
Marginal effects for the age cutoff variable (prostate): Atlantic 4.37, Ontario 3.14, British Columbia 0.21
Sample sizes (breast, women ages 40-60): Atl N = 2,745, QC N = 4,885, ON N = 6,341, Prairies N = 3,849, BC N = 2,324
Sample sizes (colorectal, adults ages 40-60): Atl N = 5,005, ON N = 12,112, SK N = 1,149, BC N = 4,722
Sample sizes (prostate, men ages 40-60): Atl N = 1,533, ON N = 3,353, BC N = 2,230
Note: Additional file 1, available in an attached document, presents the full set of regression coefficients for each of these models.Strumpf et al. BMC Cancer 2010, 10:304
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Discussion
This study examined the degree of compliance with can-
cer screening guidelines across Canadian provinces,
defined as the change in screening rates at the guideline-
recommended initiation age. We found that after control-
ling for covariates, breast cancer screening rates in Que-
bec increased at age 50 by 19 percentage points and in
Saskatchewan, colorectal cancer screening rates
increased at age 50 by nearly 13 percentage points. No
other region demonstrated compliance with screening
guidelines for these cancers and no region demonstrated
compliance with prostate cancer screening guidelines.
For breast cancer, these patterns reflected screening
among asymptomatic individuals.
Previous research in this area has focused on measur-
ing screening rates and identifying physician- or patient-
level predictors of screening. Beyond describing "high" or
"low" cancer screening rates, we defined a novel and com-
plementary definition of screening guideline compliance
and identified variation in compliance across regions.
The main result was that breast, colorectal and prostate
cancer screening rates do not change sharply at the
guideline-recommended initiation age, suggesting fairly
low compliance rates among the provinces and regions
examined here. Breast cancer screening practice in Que-
bec was quite different, and the analysis of the impact of
the provincial screening program suggested that orga-
nized screening programs can affect not only overall
screening rates, but guideline compliance as well. Of
c o u r se  t h e  Qu e bec  cas e  m a y  n o t  be  g e n e r a l iza b l e ,  b u t
more extensive data are required to conduct similar anal-
yses in other provinces. Colorectal cancer screening rates
were quite low, and with the exception of Saskatchewan,
the regions studied here did not comply with the guide-
line-recommended initiation age. On the other hand,
prostate cancer screening rates were higher than the
guidelines recommend, but we also failed to see a sharp
change in clinical practice at any particular age. We inter-
preted this as lack of compliance with Canadian screen-
ing guidelines. Future research may address whether
recent findings regarding the effectiveness of PSA testing
and changing U.S. clinical guidelines affect Canadian
compliance rates [39-41].
While Canadian guidelines recommended that breast
and colorectal cancer screening begin at age 50, the reali-
ties of clinical practice mean that screening begins
"around" that age. We looked for sharp changes in screen-
ing rates at age 50 in Figures 1, 2 and 3, but our interpre-
tation of the regression analysis only required that
average screening rates among 50-60 year olds were sig-
nificantly higher than among 40-49 year olds. If respon-
dents reported having been screened at 52 or 53, this was
consistent with the guidelines and our interpretation of
the results. Furthermore, the 2-year screening window
allowed us to capture screening at age 48 or 49 as being
guideline compliant as well.
Limitations
Due to the self-reported nature of screening in the CCHS,
it is possible that the screening rates reported here were
subject to recall bias. However, as long as any bias with
respect to accuracy or recency does not change sharply at
age 50, we do not expect such a bias to affect the change
in screening rates at the guideline-recommended initia-
tion age. In fact, analysis of screening received in the last
year yields results similar to those presented here for a 2-
year timeframe. If, however, respondents age 50 and
above are differentially accurate in their self-reports rela-
tive to younger respondents, self-reported data could
overstate the degree of guideline compliance. Existing
evidence suggests that the sensitivity of reported screen-
ing is very high across age categories, but it is also sparse,
Figure 2 Percent of Adults Who Report Colorectal Cancer Screen-
ing in the Past Two Years, by Year-of-Age, 2003 and 2005.
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Figure 3 Percent of Men Who Reported Prostate Cancer Screen-
ing in the Past Two Years, by Year-of-Age, 2003 and 2005.
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suggesting the need for additional research on this ques-
tion to help validate this measure of guideline compliance
[42].
A second limitation stems from the fact that not all
provinces included questions on all types of cancer
screening in the CCHS. Unless this was due to reasons
correlated with cancer screening patterns or policy, as
opposed to the length and cost of surveys, the results pre-
sented here are unlikely to be biased. However, this study
has demonstrated that screening patterns for different
cancers differ greatly across provinces, and therefore
inferences should not be drawn about provinces not rep-
resented in the data. Lastly, these data did not allow us to
distinguish whether guideline compliance operated
through patient behavior, physician behavior, or both.
Several other limitations stem from our study design
and variable definitions. First, we focused on screening in
the last two years, but the 5-10 year periodicity recom-
mended for sigmoidoscopy, colonoscopy and double-
contrast barium enemas by organizations other than the
CTFPHC and the CCS [43] mean that we may have
understated the degree of colorectal cancer screening
guideline compliance over a longer window. Further-
more, because we were interested in the change in
screening rates at the guideline initiation age, we focused
on a narrow range of ages (40-60) where we believed that
other determinants of screening were relatively similar.
This means, however, that we did not include individuals
who were screened above age 60 as contributing to "com-
pliance", although by more standard definitions they do.
Third, we characterized our estimates in terms of a per-
centage change in screening rates at age 50 relative to the
average rate below this age. As a result, a large absolute
change on a high base rate yielded a smaller percentage
change than a smaller absolute change on a lower base
rate. We believe this is of greater importance across can-
cers than across provinces, but presented both raw and
percentage changes so that the reader can interpret the
data in either context.
Conclusions
This analysis presented a novel definition of compliance
with cancer screening guidelines. We found low compli-
ance with cancer screening guidelines across Canadian
provinces and identified an opportunity to improve com-
pliance by reducing screening rates among younger
groups and increasing them among the guideline-recom-
mended age group. Improved compliance could have
implications for both the efficacy and cost-effectiveness
of population-based cancer screening in Canada as well
as other countries.
Several avenues exist for further research in this area,
most notably examining the relationship between guide-
line compliance and cancer-related morbidity and mor-
tality. Identifying patient- and provider-level factors that
predict compliance and examining the impact of provin-
cial colorectal cancer screening programs are other
important areas for future research.
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